ANZCTR search results

This primary aim of this study is to assess, in individuals with amnestic mild cognitive impairment, if facilitated progression towards (or meeting of) Biochemical & Physiological Targets, through participation in a 6-month personalised multimodal lifestyle Intervention will, in comparison to standard care (Control Group), cause significant improvements in cognition

Gum disease is a very common oral disease that, if not treated, may cause tooth loss. The disease is caused by bacteria that build deposits on your teeth, above and below your gums. These are known as dental plaque and these may mineralise forming dental calculus (or tartar) on tooth surfaces. Management of gum disease requires an adequate level of self-performed teeth cleaning as well as professional intervention aimed at removing dental plaque and calculus. Although this treatment is effective for most teeth, challenges arise in the management of teeth that have multiple roots, such as molars. When gum disease has progressed to involve these teeth they can be harder to maintain long term. Air polishing is a treatment modality approved by the Australian Federal Government (TGA approved) and currently used in dental treatment. AIR-FLOW®’ is a specialized device that generates a spray of air, water and powder to aid in plaque removal without additional patient discomfort. This study aims to focus on its use on maintaining molar teeth with gum disease. The research has 3 main goals 1. Identify the impact of treatments on health/stability of gums around molar teeth. 2. Identifying the impact of treatments on the level of specific bacteria around molar teeth. 3. Determining how gum disease affects quality of life. It is anticipated that the air polishing will assist in reducing the level of specific bacteria around molar teeth and provide additional improvement in the stability of gum health.

The purpose and aims of this clinical quality registry are to monitor emergency care processes and outcomes through the provision of timely extraction and analysis of ED clinical data.

This protocol aims to explore the potential effectiveness of topical eucalypt sap resin application across a range of both acute and chronic skin injury and inflammatory conditions, using this novel Australian native ingredient with antimicrobial, styptic, and astringent properties. Skin conditions to be evaluated as individual case studies under this protocol cover wound care (both acute and chronic), fungal skin infections, acne, insect bites and sunburn.

The purpose of this study is to generate key data in preparation for the Phase I/II study (safety, immunogenicity and descriptive efficacy proof of concept), and for the global Phase III vaccine efficacy study as part of the Chlamydia vaccine clinical development program. This study will monitor urogenital and extragenital infections or reinfections caused by Chlamydia trachomatis bacteria. Study details It is an observational study, and no vaccine will be administered. This study plans to identify and follow approximately 200 participants Ct NAAT positive from collected urogenital samples for a maximum of 7 months. Females will have vaginal, cervical (optional), oropharyngeal (optional), rectal (optional), and mucosal vaginal secretion (optional) samples collected and males will provide urine, oropharyngeal (optional), rectal (optional), and urethral (optional) samples for the detection of Ct infection. Study duration- The study duration will be variable depending on the baseline Ct infection status and Ct reinfection but will not exceed 7 months. -

In this randomised, double-blind, placebo-controlled study, 120 adults with Long COVID aged 18 to 65 years will be randomly assigned to receive a liquid herbal formula (SRS-MHT-44) daily or a placebo for 8 weeks. Changes in general wellbeing and quality of life will be assessed over time by administering several questionnaires. Moreover, changes in several biomarkers associated with inflammation, immunity, cardiovascular health, and general health will be evaluated over time. It is hypothesised that intake of the liquid herbal formula will lead to changes in Long-COVID related symptoms and blood markers associated with immunity, renal, cardiac and general health.

Participants with a diagnosis of heart failure with preserved ejection fraction (HFpEF) will undergo a cardiac MRI to see if any structural heart changes can be used to predict those who are high-risk for progression of disease. Weight changes, hospitalizations, and symptom will be tracked every 6-months for a minimum of 3 years, and linking data with the National Death Index will allow us to identify patterns between heart failure and cardiac-related death. This data will allow the implementation of screening with MRI and early intervention for high-risk groups.

Diabetics on the study drug, tirzepatide, have been shown to experience significant weight loss during their treatment with this medication. Our study aims to identify its mechanism of action for patients with heart failure with preserved ejection fraction (HFpEF) and examine if treatment with this medication can significantly improve structural, functional, and symptomatic outcomes of patients with heart failure.

ADHD is a common neurodevelopmental disorder defined by the persistence of dysregulated attention, activity and impulsivity. The incidence of ADHD in childhood is 6-7%. Some symptoms improve in adolescence, but 2–4% of adults continue to meet the diagnostic criteria. ADHD is recognised in 3 to 4 times as many people seeking help for substance use disorder (SUD) as in the general population. Adults with ADHD who use drugs are often misdiagnosed and cannot access effective, targeted, multidisciplinary care. Individual specialists and specialist services will not treat ADHD in the presence of SUD. This project aims to demonstrate that recognition of ADHD and active management significantly improve quality of life and reduce substance use in people seeking help for SUD.

Mesothelioma is an aggressive cancer with limited treatment options. We have conducted studies of a specific extract from Leptospermum petersonii (QV0; lemon scent tea tree) which showed reduction of cancer activities in the petri dish and also reduction of tumour in mice studies. This project is a first-in-human study of Leptospermum petersonii extract. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with mesothelioma. Study details All participants will be provided with Leptospermum petersonii extract to take by mouth for 6 weeks. Every 6 weeks, the dose of extract will be increased for 24 weeks. During this time, participants will be asked to provide blood, stool and urine samples, complete questionnaires, and will be monitored for side effects. It is hoped that this study will help determine if Leptospermum petersonii extract can be used safely in humans to control cancer by itself or in combination with other conventional treatment in mesothelioma patients